Vitiligo Types, Progression, and What Patients Fear Most

Welcome back to another AJMC Peer Exchange series. In "Vitiligo Types, Progression, and What Patients Fear Most," moderator Ryan Haumschild, PharmD, MS, MBA, CPEL is joined by David Rosmarin, MD, Seemal Desai, MD, FAAD, Jason Fehr, MA, and Karan Lal, DO, MS, FAAD to open the discussion on vitiligo, starting with how the panel distinguishes segmental from non-segmental disease and identifies patients who need urgent care.

Dr. Rosmarin opens the clinical discussion by dividing vitiligo into two broad categories: segmental and non-segmental disease. Segmental vitiligo, he explains, appears mostly in pediatric patients and affects a single body region. It develops rapidly over six months to two years, then remains stable for life, though it carries a somewhat poorer prognosis. Non-segmental vitiligo, the far more common form, shares the same underlying autoimmune mechanism but behaves less predictably. It can be active or stable at different points in a patient's life, and its extent can range from minimal to widespread.

Dr. Rosmarin describes three sequential goals that guide treatment once a patient is diagnosed. The first step is determining whether disease is active or stable, since active disease demands halting progression before anything else. Once progression stops, the second goal becomes repigmenting affected skin. The third and final goal is maintaining that repigmentation over time. This staged framework, he explains, determines his next clinical step whenever he evaluates a new or returning patient.

Dr. Haumschild then asks what concern patients raise most often at diagnosis. Dr. Rosmarin answers that published data confirm what he sees clinically: patients worry above all that their disease will spread, particularly to visible areas like the face. Fear of new facial involvement, or of disease reaching areas not yet affected, dominates almost every initial conversation he has with newly diagnosed patients. Dr. Haumschild closes by noting how this patient-centered concern about visible spread should shape not just the clinical approach, but also how providers frame urgency and monitoring decisions for each individual case going forward.

The next episode in this series, "Why Body Surface Area Alone Doesn't Capture Vitiligo Severity," features Dr. Lal and Dr. Rosmarin examining why body surface area alone can understate disease severity.